Here the authors report a retrospective analysis showing lower risk of composite outcomes of all-cause hospitalization, all-cause mortality, major adverse cardiovascular events, major adverse kidney events and major adverse liver outcomes for patients with MASLD treated with combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy. However, a sensitivity analyses suggests that these effects may be driven by the GLP-1 receptor agonist treatment.
- Jheng-Yan Wu
- Wan-Hsuan Hsu
- Chih-Cheng Lai
